Hepatitis C virus infection (HepCV) is a significant health issue globally, which leads to several liver diseases, including cirrhosis and hepatocellular carcinomas. There is a class of drugs knowns as DAA, which has changed the spectrum of chronic HepCV treatment modality. HepCV genotype 3 is more prevalent in Pakistan and more aggressive, leading to HCC. We studied the drug response in SVR or sustained virological response in HepCV-infected patients on daclatasvir and sofosbuvir compared to sofosbuvir ribavirin in the local population.